EMINENT Initiative – Cambridge key player in the successful £16 million consortium bid to crack difficult inflammatory diseases such as COPD and Fibrosis
Cambridge was part of a successful £16 million bid to work with the MRC, GSK and four other UK universities to improve scientists’ understanding of inflammatory and fibrotic diseases using experimental medicine approaches. The successful bid was led for Cambridge by Professor Edwin Chilvers from the Department of Medicine FMedSci and co-ordinated by the Office for Translational Research. Individual themes will also be lead by Professor Ken Smith, Professor Arthur Kaser and Dr David Jayne all from the Department of Medicine. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will bring together teams of researchers from Universities of Cambridge, Glasgow, Newcastle, Imperial College and UCL with GSK researchers. It is hoped that combining the disease biology expertise of the academic scientists with GSK’s drug development programme will lead to breakthroughs that will accelerate the development of new and innovative treatments. Through the EMINENT network, MRC funding of £8m over five years will support academic costs with a similar contribution from GSK. The initiative aims to support up to ten experimental medicine projects over five years.
Link to full story: See more at: http://www.cam.ac.uk/news/mrc-gsk-and-five-leading-uk-universities-collaborate-to-crack-difficult-disease-areas#sthash.UEzr7jZ7.dpuf
A chest X-ray demonstrating severe COPD (cropped)
Credit: James Heilman, MD